19 research outputs found

    Ультрадисперсные порошки на основе железа как катализаторы синтеза жидких углеводородов из СО и Н[2]

    Get PDF
    International audienceTo date, uniparental disomy (UPD) with phenotypic relevance is described for different chromosomes and it is likely that additional as yet unidentified UPD phenotypes exist. Due to technical difficulties and limitations of time and resources, molecular analyses for UPD using microsatellite markers are only performed in cases with specific phenotypic features. In this study, we carried out a whole genome UPD screening based on a microarray genotyping technique. Six patients with the diagnosis of both complete or segmental UPD including Prader-Willi syndrome (PWS; matUPD15), Angelman syndrome (AS; patUPD15), Silver-Russell syndrome (SRS; matUPD7), Beckwith-Wiedemann syndrome (BWS; patUPD11p), pseudohypoparathyroidism (PHP; patUPD20q) and a rare chromosomal rearrangement (patUPD2p, matUPD2q), were genotyped using the GeneChip Human Mapping 10K Array. Our results demonstrate the presence of UPD in the patients with high efficiency and reveal clues about the mechanisms of UPD formation. We thus conclude that array based SNP genotyping is a fast, cost-effective, and reliable approach for whole genome UPD screening

    A Kinematical Approach to Conformal Cosmology

    Get PDF
    We present an alternative cosmology based on conformal gravity, as originally introduced by H. Weyl and recently revisited by P. Mannheim and D. Kazanas. Unlike past similar attempts our approach is a purely kinematical application of the conformal symmetry to the Universe, through a critical reanalysis of fundamental astrophysical observations, such as the cosmological redshift and others. As a result of this novel approach we obtain a closed-form expression for the cosmic scale factor R(t) and a revised interpretation of the space-time coordinates usually employed in cosmology. New fundamental cosmological parameters are introduced and evaluated. This emerging new cosmology does not seem to possess any of the controversial features of the current standard model, such as the presence of dark matter, dark energy or of a cosmological constant, the existence of the horizon problem or of an inflationary phase. Comparing our results with current conformal cosmologies in the literature, we note that our kinematic cosmology is equivalent to conformal gravity with a cosmological constant at late (or early) cosmological times. The cosmic scale factor and the evolution of the Universe are described in terms of several dimensionless quantities, among which a new cosmological variable delta emerges as a natural cosmic time. The mathematical connections between all these quantities are described in details and a relationship is established with the original kinematic cosmology by L. Infeld and A. Schild. The mathematical foundations of our kinematical conformal cosmology will need to be checked against current astrophysical experimental data, before this new model can become a viable alternative to the standard theory.Comment: Improved version, with minor changes. 58 pages, including 7 figures and one table. Accepted for publication in General Relativity and Gravitation (GERG

    Sloan Digital Sky Survey IV: Mapping the Milky Way, Nearby Galaxies, and the Distant Universe

    Get PDF
    We describe the Sloan Digital Sky Survey IV (SDSS-IV), a project encompassing three major spectroscopic programs. The Apache Point Observatory Galactic Evolution Experiment 2 (APOGEE-2) is observing hundreds of thousands of Milky Way stars at high resolution and high signal-to-noise ratios in the near-infrared. The Mapping Nearby Galaxies at Apache Point Observatory (MaNGA) survey is obtaining spatially resolved spectroscopy for thousands of nearby galaxies (median z0.03z\sim 0.03). The extended Baryon Oscillation Spectroscopic Survey (eBOSS) is mapping the galaxy, quasar, and neutral gas distributions between z0.6z\sim 0.6 and 3.5 to constrain cosmology using baryon acoustic oscillations, redshift space distortions, and the shape of the power spectrum. Within eBOSS, we are conducting two major subprograms: the SPectroscopic IDentification of eROSITA Sources (SPIDERS), investigating X-ray AGNs and galaxies in X-ray clusters, and the Time Domain Spectroscopic Survey (TDSS), obtaining spectra of variable sources. All programs use the 2.5 m Sloan Foundation Telescope at the Apache Point Observatory; observations there began in Summer 2014. APOGEE-2 also operates a second near-infrared spectrograph at the 2.5 m du Pont Telescope at Las Campanas Observatory, with observations beginning in early 2017. Observations at both facilities are scheduled to continue through 2020. In keeping with previous SDSS policy, SDSS-IV provides regularly scheduled public data releases; the first one, Data Release 13, was made available in 2016 July

    Praxisorientierte Psychotherapieforschung

    No full text
    Praxisorientierte Psychotherapieforschung und insbesondere verfahrensübergreifende, patientenorientierte Aspekte stellen den aktuellen State of the Art dar, der die Interessen der Praxis sowie die akademischen Anforderungen sinnvoll verbindet. Der vorliegende Leitfaden dient als Orientierungshilfe in Bezug auf Grundlagen für Wissenschaft und Forschung in der psychotherapeutischen Ausbildung und möchte ein verfahrensübergreifendes Selbstverständnis von wissenschaftlich fundierter Psychotherapie fördern. Teil A "Theorie der Psychotherapieforschung" stellt die aktuellen Erkenntnisse zur wissenschaftstheoretischen Reflexion, zu Paradigmen, Gütekriterien und Zielsetzungen der (praxisorientierten) Psychotherapieforschung dar. Im Teil B "Praxis der Psychotherapieforschung" werden die umsetzungsorientierten Aspekte zu Forschungsansätzen,-designs und -methoden sowie Qualitätskriterien für wissenschaftliche Arbeiten anwendungsorientiert aufbereitet. Teil C enthält abgeleitete Empfehlungen für die psychotherapeutischen Ausbildungsvereine, die auf einem Stufenplan zur Förderung von Wissenschaft und Forschung in den psychotherapeutischen Ausbildungseinrichtungen basieren

    PolyQ-expanded ataxin-3 protein levels in peripheral blood mononuclear cells correlate with clinical parameters in SCA3: a pilot study

    No full text
    In view of upcoming clinical trials, quantitative molecular markers accessible in peripheral blood are of critical importance as prognostic or pharmacodynamic markers in genetic neurodegenerative diseases such as Spinocerebellar Ataxia Type 3 (SCA3), in particular for signaling target engagement. In this pilot study, we focused on the quantification of ataxin-3, the protein altered in SCA3, in human peripheral blood mononuclear cells (PBMCs) acquired from preataxic and ataxic SCA3 mutation carriers as well as healthy controls, as a molecular marker directly related to SCA3 pathophysiology. We established two different highly sensitive TR-FRET-based immunoassays to measure the protein levels of either total full-length, non-expanded and expanded, ataxin-3 or specifically polyQ-expanded ataxin-3. In PBMCs, a clear discrimination between SCA3 mutation carrier and controls were seen measuring polyQ-expanded ataxin-3 protein level. Additionally, polyQ-expanded ataxin-3 protein levels correlated with disease progression and clinical severity as assessed by the Scale for the Assessment and Rating of Ataxia. Total full-length ataxin-3 protein levels were directly influenced by the expression levels of the polyQ-expanded ataxin-3 protein, but were not correlated with clinical parameters. Assessment of ataxin-3 levels in fibroblasts or induced pluripotent stem cells allowed to distinguish mutation carriers from controls, thus providing proof-of-principle validation of our PBMC findings across cell lines. Total full-length or polyQ-expanded ataxin-3 protein was not detectable by TR-FRET assays in other biofluids like plasma or cerebrospinal fluid, indicating the need for ultra-sensitive assays for these biofluids. Standardization studies revealed that tube systems, blood sampling, and PBMC preparation may influence ataxin-3 protein levels indicating a high demand for standardized protocols in biomarker studies. In conclusion, the polyQ-expanded ataxin-3 protein is a promising candidate as a molecular target engagement marker in SCA3 in future clinical trials, determinable even in-easily accessible-peripheral blood biomaterials. These results, however, require validation in a larger cohort and further standardization of modifying conditions
    corecore